Relationship of Serum Resistin Level to Traits of Metabolic Syndrome and Serum Paraoxonase 1 Activity in a Population with a Broad Range of Body Mass Index

Abstract

The relationship between resistin, one of the adipokines, and metabolic syndrome is not fully elucidated. Altered activity of the HDL-associated antioxidant enzyme paraoxonase 1 (PON1) that participates in the antioxidant defense mechanisms of HDL may have an important role in the obesity-related accelerated atherosclerosis. Inverse associations of PON1 with obesity and serum levels of leptin have been demonstrated. Our aim was to investigate the association of serum levels of resistin with (i) PON1 activity, and (ii) parameters of metabolic syndrome, including some that are additional for research. A total of 74 Caucasian subjects were recruited into the study and divided into 3 age and sex-matched groups. Group 1, 25 non-diabetic overweight/obese subjects with BMI of 28–39.9 kg/m²; group 2, 25 non-diabetic obese patients with BMI ≥40 kg/m²; and the control group 3, 24 healthy, normal-weight control subjects. Serum levels of resistin were correlated negatively with BMI (r=−0.27, P<0.05), waist circumference (r=−0.28, P<0.05), serum levels of leptin (r=−0.28, P<0.05), non-esterified fatty acids (NEFA) (r=−0.23, P<0.05), and HbA_1C (r=−0.26, P<0.05), systolic BP (r=−0.28, P<0.05), and lipid peroxidation (measured by TBARS) (r=−0.40, P<0.01), and correlated positively with PON1 (r=0.24, P<0.05). No association was detected between the serum concentrations of resistin and the following investigated parameters: diastolic BP, levels of uric acid, glucose, insulin, or insulin resistance (measured by homeostasis model assessment, HOMA-IR), triglyceride, total cholesterol, LDL-C, and HDL-C. During multiple regression analyses BMI and TBARS were independent predictors of PON1, while age, gender, blood pressure, HOMA-IR, LDL-C, HDL-C, and resistin were not.

Conclusions: Among the study subjects, serum levels of resistin showed a positive, although not independent correlation with serum PON1, and a negative correlation with numerous parameters of the metabolic syndrome (i.e. adiposity, blood pressure, levels of leptin, free fatty acid, glycosylated hemoglobin, and lipid peroxidation). BMI and TBARS are independent predictors of PON1 activity.

obesity - resistin - serum paraoxonase 1 - metabolic syndrome

References

• 1 Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins.  Arterioscler Thromb Vasc Biol. 1995;  15 1812-1818
• 2 Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group . The metabolic syndrome–a new worldwide definition.  Lancet. 2005;  366 1059-1062
• 3 Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.  Free Radic Biol Med. 1999;  26 892-904
• 4 Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, Saruta T. Correlation between serum resistin level and adiposity in obese individuals.  Obes Res. 2003;  11 997-1001
• 5 Chen CC, Li TC, Li CI, Liu CS, Wang HJ, Lin CC. Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters.  Metabolism. 2005;  54 471-475
• 6 Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV. Serum resistin (FIZZ3) protein is increased in obese humans.  J Clin Endocrinol Metab. 2003;  88 5452-5455
• 7 Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M. Resistin release by human adipose tissue explants in primary culture.  Biochem Biophys Res Commun. 2003;  300 674-678
• 8 Fehmann HC, Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls.  Horm Metab Res. 2002;  34 671-673
• 9 Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, Bicchiega V. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females.  J Clin Endocrinol Metab. 2005;  90 1728-1733
• 10 Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, Kawahara Y, Yamazaki M, Ogata M, Hasegawa G, Nakamura N, Yoshikawa T, Nakano K, Ohta M. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes.  Clin Chim Acta. 2004;  339 57-63
• 11 Galli F, Varga Zs, Balla J, Ferraro B, Canestrari F, Floridi A, Kakuk G, Buoncristiani U. Vitamin E, lipid profile, and peroxidation in hemodialysis patients.  Kidney Int. 2001;  59 ((Suppl 78)) 148-154
• 12 Getz GS, Reardon CA. Paraoxonase, a cardioprotective enzyme: continuing issues.  Curr Opin Lipidol. 2004;  15 261-267
• 13 Hegele RA, Kraw ME, Ban MR, Miskie BA, Huff MW, Cao H. Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy.  Arterioscler Thromb Vasc Biol. 2003;  23 111-116
• 14 Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro.  Biochem Biophys Res Commun. 2003;  309 286-290
• 15 Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects.  J Clin Endocrinol Metab. 2003;  88 4848-4856
• 16 Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, Li K. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.  Exp Clin Endocrinol Diabetes. 2006;  114 544-548
• 17 Lu SC, Shieh WY, Chen CY, Hsu SC, Chen HL. Lipopolysaccharide increases resistin gene expression in vivo and in vitro.  FEBS Lett. 2002;  530 158-162
• 18 Mackness B, Durrington P, MacElduff P, Yarnell J, Azam N, Watt M, Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study.  Circulation. 2003;  107 2775-2779
• 19 Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus.  Atherosclerosis. 1991;  86 193-199
• 20 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 21 MacTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, MacTernan CL, Clark PM, Smith SA, Barnett AH, Kumar S. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes.  J Clin Endocrinol Metab. 2003;  88 6098-6106
• 22 Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators.  Biochem Biophys Res Commun. 2003;  300 472-476
• 23 Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance.  Clin Lab. 2003;  49 571-576
• 24 Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production.  J Clin Invest. 2003;  111 225-230
• 25 Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans.  Circulation. 2005;  111 932-939
• 26 Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux.  J Biol Chem. 2006;  281 7657-7665
• 27 Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O’Rahilly S. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans.  Diabetes. 2001;  50 2199-2202
• 28 Seow KM, Juan CC, Wu LY, Hsu YP, Yang WM, Tsai YL, Hwang JL, Ho LT. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance.  Hum Reprod. 2004;  19 48-53
• 29 Seres I, Paragh G, Deschene E, Fulop Jr T, Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging.  Exp Gerontol. 2004;  39 59-66
• 30 Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance.  Eur J Endocrinol. 2003;  149 331-335
• 31 Smolen A, Eckerson HW, Gan KN, Hailat N, La Du BN. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase.  Drug Metab Dispos. 1991;  19 107-112
• 32 Staiger H, Häring HU. Adipocytokines: Fat-derived humoral mediators of metabolic homeostasis.  Exp Clin Endocrinol Diabetes. 2005;  113 67-79
• 33 Volarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians.  Diabetes. 2004;  53 1279-1284
• 34 Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein.  J Clin Invest. 1995;  96 2882-2891
• 35 Yang RZ, Huang Q, Xu A, MacLenithan JC, Eisen JA, Shuldiner AR, Alkan S, Gong DW, Eison JA. Comparative studies of resistin expression and phylogenomics in human and mouse.  Biochem Biophys Res Commun. 2003;  310 927-935
• 36 Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans.  J Clin Endocrinol Metab. 2003;  88 1730-1736
• 37 Yudkin JS. Inflammation, obesity, and the metabolic syndrome.  Horm Metab Res. 2007;  39 707-709

Correspondence